BeiGene, Ltd. (BGNE) News
Filter BGNE News Items
BGNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BGNE News Highlights
- BGNE's 30 day story count now stands at 7.
- Over the past 22 days, the trend for BGNE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about BGNE are NICE, WM and AG.
Latest BGNE News From Around the Web
Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
Latest Push by Chinese Firms to Avoid Delistings Falls Short(Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remark |
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood CancerEngland's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable. This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales. Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia |
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One TreatmentCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström’s Macroglobulinemia (WM) in adults who have |
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone LymphomaCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of BRUKINSA ® (zanubrutinib) for the treatment o |
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid TumorsBeiGene Limited (NASDAQ: BGNE) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. The Phase 3 RATIONALE 301 trial of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma met its primary endpoint of overall survival (OS) non-inferiority. The median OS was 15.9 months for tislelizumab compared to 14.1 months for Bayer AG (OTC: BAYRY) Nexavar (sorafenib). Rela |
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular CancerCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 10, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid tumor development program for cornerstone PD-1 antibody tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. |
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 07, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, 2022 with a fireside chat at 9:10 a.m. ET. |
7 Chinese Stocks to Sell While You Still CanThese Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure |
U.S.-China relations just got a whole lot better, boosting the prospects of these three stocksSecurities regulators in the two countries came to an agreement on audit protocols, lifting an overhang on Chinese stocks. |
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in ChinaCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, August 23, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab |